10-Q 1 lgvn-20240930.htm 10-Q 10-Q
--12-31Q3flase00017214844 years and 6 months5 years and 6 monthseighteen months0001721484us-gaap:LeaseholdImprovementsMember2023-12-310001721484us-gaap:AdditionalPaidInCapitalMember2024-06-300001721484lgvn:TwoThousandTwentyOnePIPEOfferingMemberus-gaap:CommonClassAMemberlgvn:UnderwritersWarrantsMember2024-01-012024-09-300001721484us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2024-01-012024-09-300001721484us-gaap:CommonClassAMemberlgvn:UnderwritersWarrantsMemberus-gaap:IPOMember2024-01-012024-09-300001721484us-gaap:FairValueInputsLevel3Memberus-gaap:AllOtherCorporateBondsMember2023-12-310001721484us-gaap:ComputerEquipmentMember2023-12-310001721484lgvn:SeriesAAndSeriesBWarrantsMember2024-09-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-12-310001721484us-gaap:PatentsMember2023-12-310001721484us-gaap:FairValueInputsLevel2Member2023-12-310001721484us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001721484lgvn:JulyPrivatePlacementMember2024-08-0600017214842024-06-300001721484lgvn:RockSofferMember2024-07-012024-09-300001721484lgvn:ContractManufacturingMember2024-01-012024-09-300001721484us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001721484us-gaap:CommonClassAMemberlgvn:PreFundedWarrantMember2024-04-080001721484us-gaap:ValuationTechniqueConsensusPricingModelMember2023-08-160001721484us-gaap:CommonClassAMemberlgvn:SeriesDWarrantsMember2024-06-170001721484us-gaap:MoneyMarketFundsMember2024-09-300001721484us-gaap:CommonClassAMemberus-gaap:WarrantMember2024-04-162024-04-160001721484lgvn:ClinicalTrialRevenueMember2024-07-012024-09-300001721484lgvn:ChiefScienceOfficerMember2024-09-300001721484us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-06-300001721484us-gaap:MoneyMarketFundsMember2023-12-310001721484us-gaap:SeriesAMember2024-09-300001721484lgvn:SeriesCWarrantsMemberus-gaap:CommonClassAMember2024-09-300001721484us-gaap:CommonClassAMemberus-gaap:IPOMember2024-09-300001721484us-gaap:StockOptionMemberus-gaap:CommonClassAMember2024-04-300001721484us-gaap:StockOptionMember2023-07-012023-09-300001721484lgvn:TwoThousandTwentyOnePIPEOfferingMemberus-gaap:CommonClassAMember2024-09-3000017214842023-12-310001721484us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2024-09-300001721484us-gaap:CommonClassAMember2024-07-180001721484us-gaap:PhantomShareUnitsPSUsMember2023-01-012023-09-3000017214842024-07-172024-07-170001721484us-gaap:CommonClassAMember2024-07-100001721484lgvn:FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMemberus-gaap:CommonClassAMember2024-01-012024-09-3000017214842024-01-012024-09-300001721484us-gaap:AccruedIncomeReceivableMember2024-09-300001721484us-gaap:FairValueInputsLevel2Memberus-gaap:AllOtherCorporateBondsMember2023-12-310001721484us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001721484us-gaap:RetainedEarningsMember2023-12-310001721484us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-09-300001721484us-gaap:CommonClassAMemberlgvn:JulyPrivatePlacementMember2024-09-300001721484us-gaap:CommonClassAMemberus-gaap:WarrantMember2024-09-300001721484us-gaap:StockOptionMember2024-01-012024-09-300001721484lgvn:OctoberTwoThousandTwentyFourInducementTransactionPurchaserWarrantsMemberus-gaap:CommonClassAMemberus-gaap:SubsequentEventMember2024-10-310001721484us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-09-300001721484us-gaap:AdditionalPaidInCapitalMember2023-06-300001721484srt:MinimumMember2024-09-300001721484us-gaap:SeriesBMember2024-09-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-01-012023-09-300001721484us-gaap:AllOtherCorporateBondsMember2023-12-310001721484lgvn:SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMemberus-gaap:CommonClassAMember2024-01-012024-09-300001721484lgvn:TwoThousandTwentyOnePIPEOfferingMemberus-gaap:WarrantMember2024-09-300001721484lgvn:NationalInstitutesOfHealthGrantMember2024-01-012024-09-300001721484lgvn:AprilTwoThousandTwentyFourPublicOfferingMemberlgvn:PlacementAgentWarrantsMemberus-gaap:CommonClassAMember2024-01-012024-09-300001721484us-gaap:SeriesBMemberlgvn:October2023RegisteredDirectOfferingMember2024-09-300001721484us-gaap:FairValueInputsLevel3Member2023-12-310001721484srt:MaximumMember2024-09-300001721484us-gaap:StockOptionMember2023-12-310001721484us-gaap:CommonClassAMemberlgvn:UnderwritersMember2021-12-310001721484us-gaap:WarrantMember2023-01-012023-09-300001721484us-gaap:CommonClassAMemberlgvn:JunePlacementAgentWarrantsMember2024-01-012024-09-300001721484us-gaap:ReceivablesFromStockholderMember2022-12-3100017214842023-01-012023-09-300001721484us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001721484us-gaap:CommonClassAMemberlgvn:SeriesDWarrantsMember2024-09-300001721484lgvn:FirstTrancheJulyOrdinaryCoursePlacementAgentWarrantsMemberus-gaap:CommonClassAMember2024-09-300001721484us-gaap:CommonStockMemberlgvn:SeriesDWarrantsMember2024-01-012024-09-300001721484us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonClassAMember2024-04-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-12-310001721484us-gaap:CommonStockMemberlgvn:CommonWarrantsMember2024-04-080001721484us-gaap:LeaseholdImprovementsMember2024-09-300001721484us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-12-310001721484us-gaap:FairValueInputsLevel1Memberus-gaap:AccruedIncomeReceivableMember2023-12-310001721484us-gaap:RetainedEarningsMember2023-09-300001721484srt:MaximumMember2024-07-012024-09-300001721484us-gaap:FurnitureAndFixturesMember2024-09-300001721484us-gaap:FairValueInputsLevel3Memberus-gaap:AccruedIncomeReceivableMember2023-12-310001721484us-gaap:RestrictedStockUnitsRSUMember2024-09-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-06-300001721484us-gaap:FairValueInputsLevel2Memberus-gaap:AccruedIncomeReceivableMember2023-12-310001721484us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001721484us-gaap:SoftwareDevelopmentMember2024-09-300001721484us-gaap:CommonClassAMember2024-06-170001721484lgvn:SeriesCWarrantsMember2024-04-160001721484srt:MaximumMember2023-07-012023-09-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-01-012024-09-300001721484lgvn:SeriesCWarrantsAndSeriesDWarrantsMember2024-04-160001721484us-gaap:CommonClassAMemberlgvn:SeriesDWarrantsMember2024-06-172024-06-170001721484us-gaap:CommonClassAMemberlgvn:JulyPrivatePlacementMember2024-01-012024-09-300001721484us-gaap:CommonClassAMember2014-11-200001721484srt:MinimumMember2023-09-300001721484lgvn:TwoThousandTwentyOnePIPEOfferingMemberus-gaap:CommonClassAMember2024-09-012024-09-300001721484lgvn:SeriesDWarrantsMember2024-09-300001721484us-gaap:ComputerEquipmentMember2024-09-3000017214842022-11-162022-11-160001721484lgvn:firstPhase3ClinicalTrialMember2014-11-202014-11-2000017214842024-07-192024-07-190001721484us-gaap:ReceivablesFromStockholderMember2023-12-310001721484srt:MinimumMember2024-01-012024-09-300001721484lgvn:SupplyAgreementMemberlgvn:SecretomeTherapeuticsIncorporatedMember2024-01-012024-09-300001721484lgvn:NationalInstitutesOfHealthGrantMember2023-01-012023-09-300001721484us-gaap:ValuationTechniqueConsensusPricingModelMember2023-08-162023-08-1600017214842023-01-012023-12-310001721484lgvn:ClassACommonStockWarrantsMember2024-06-172024-06-170001721484lgvn:JuneInducementWarrantsMember2024-01-012024-09-3000017214842024-07-012024-09-300001721484us-gaap:TrademarksMember2023-12-310001721484us-gaap:CommonClassAMemberlgvn:SeriesDWarrantsMember2024-01-012024-09-300001721484lgvn:AccountsReceivableFromCustomersMember2023-12-310001721484us-gaap:RetainedEarningsMember2022-12-310001721484us-gaap:LicensingAgreementsMember2023-12-310001721484us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-09-300001721484us-gaap:CommonClassAMember2023-12-310001721484us-gaap:CommonClassBMember2023-12-310001721484lgvn:ContractManufacturingMember2023-07-012023-09-300001721484us-gaap:TrademarksMember2024-09-300001721484us-gaap:CommonClassAMemberlgvn:UnderwritersWarrantsMemberus-gaap:IPOMember2024-09-300001721484lgvn:December2023OfferingMemberus-gaap:CommonClassAMemberlgvn:InvestorWarrantsMember2024-09-300001721484us-gaap:ReceivablesFromStockholderMember2023-09-300001721484us-gaap:AdditionalPaidInCapitalMember2024-09-300001721484lgvn:PlacementAgentWarrantsMemberlgvn:December2023OfferingMemberus-gaap:CommonClassAMember2024-09-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-01-012024-09-300001721484lgvn:PreFundedWarrantMember2024-04-080001721484us-gaap:CommonClassAMemberlgvn:JunePlacementAgentWarrantsMember2024-09-300001721484lgvn:RockSofferMember2024-09-300001721484us-gaap:StockOptionMember2024-07-012024-09-300001721484lgvn:TwoThousandTwentyOnePIPEOfferingMember2024-09-300001721484us-gaap:CommonClassAMemberlgvn:JulyOfferingPlacementMember2024-01-012024-09-300001721484us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001721484us-gaap:CommonClassBMember2024-11-080001721484us-gaap:FiniteLivedIntangibleAssetsMember2024-09-3000017214842016-12-232016-12-230001721484us-gaap:CommonClassAMemberus-gaap:WarrantMember2024-01-012024-09-300001721484us-gaap:AllOtherCorporateBondsMemberus-gaap:FairValueInputsLevel1Member2023-12-310001721484us-gaap:CommonClassAMemberlgvn:PlacementAgentWarrants1Member2024-09-300001721484lgvn:UMAgreementsMember2024-01-012024-09-300001721484us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001721484lgvn:JulyOrdinaryCoursePlacementAgentMember2024-08-060001721484us-gaap:CommonClassBMember2024-01-012024-09-300001721484us-gaap:WarrantMember2024-01-012024-09-300001721484lgvn:December2023OfferingMemberus-gaap:CommonClassAMember2024-09-300001721484us-gaap:RetainedEarningsMember2023-07-012023-09-300001721484lgvn:NondisclosureAgreementMemberlgvn:SecretomeTherapeuticsIncorporatedMember2023-10-242023-10-240001721484us-gaap:CommonClassAMember2024-01-012024-09-300001721484lgvn:October2023RegisteredDirectOfferingMemberus-gaap:SeriesAMember2024-09-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-12-310001721484us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2023-12-310001721484us-gaap:SeriesBMember2024-01-012024-09-300001721484us-gaap:WarrantMember2024-04-160001721484lgvn:TechnologyServicesAgreementMember2024-09-300001721484us-gaap:StockOptionMember2024-09-300001721484lgvn:SeriesCWarrantsMemberus-gaap:CommonClassAMember2024-01-012024-09-300001721484lgvn:December2023OfferingMemberlgvn:UnderwritersWarrantsMember2024-09-300001721484us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310001721484us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2024-09-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-07-012023-09-300001721484us-gaap:AdditionalPaidInCapitalMember2023-09-300001721484us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001721484us-gaap:CommonClassAMember2024-09-300001721484us-gaap:FurnitureAndFixturesMember2023-12-310001721484lgvn:SupplyAgreementMemberlgvn:SecretomeTherapeuticsIncorporatedMember2024-02-212024-02-210001721484lgvn:PlacementAgentWarrantsMemberus-gaap:CommonClassAMember2024-09-300001721484lgvn:CommonWarrantsMember2024-09-300001721484us-gaap:RetainedEarningsMember2024-07-012024-09-300001721484us-gaap:RetainedEarningsMember2023-01-012023-09-300001721484lgvn:TwoThousandTwentyOnePIPEOfferingMemberus-gaap:SubsequentEventMember2024-10-310001721484us-gaap:FairValueInputsLevel3Member2024-09-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-06-300001721484lgvn:ClinicalTrialRevenueMember2023-07-012023-09-300001721484lgvn:TechnologyServicesAgreementMember2023-12-310001721484lgvn:SeriesCWarrantsMember2024-07-100001721484us-gaap:CommonClassAMember2024-07-102024-07-100001721484us-gaap:ReceivablesFromStockholderMember2024-01-012024-09-300001721484us-gaap:CommonClassAMemberlgvn:JuneInducementWarrantsMember2024-01-012024-09-300001721484lgvn:ClinicalTrialRevenueMember2024-01-012024-09-300001721484us-gaap:LicenseMember2021-01-012021-12-310001721484lgvn:TwoThousandTwentyOnePIPEOfferingMemberus-gaap:CommonClassAMemberus-gaap:WarrantMember2024-09-300001721484us-gaap:CommonClassAMemberus-gaap:IPOMember2024-04-080001721484us-gaap:RestrictedStockUnitsRSUMember2023-12-310001721484us-gaap:CommonClassAMemberlgvn:PlacementAgentWarrants1Member2024-01-012024-09-300001721484lgvn:JulyOfferingPlacementMember2024-08-060001721484lgvn:NationalInstitutesOfHealthGrantMember2023-07-012023-09-300001721484us-gaap:SoftwareDevelopmentMember2023-12-310001721484lgvn:SupplyAgreementMemberlgvn:SecretomeTherapeuticsIncorporatedMember2024-02-210001721484lgvn:NationalInstitutesOfHealthGrantMember2024-07-012024-09-300001721484lgvn:AprilTwoThousandTwentyFourPublicOfferingMemberus-gaap:CommonClassAMemberlgvn:CommonWarrantsMember2024-09-300001721484lgvn:NationalInstitutesOfHealthGrantMember2023-12-310001721484us-gaap:LicensingAgreementsMember2024-09-300001721484us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001721484us-gaap:WarrantMemberus-gaap:NoteWarrantMember2024-01-012024-09-300001721484us-gaap:CommonClassAMemberlgvn:JulyOfferingPlacementMember2024-09-300001721484lgvn:NationalInstitutesOfHealthGrantMember2024-09-300001721484us-gaap:WarrantMember2024-01-012024-09-300001721484srt:MaximumMemberus-gaap:FiniteLivedIntangibleAssetsMember2024-09-300001721484us-gaap:FairValueInputsLevel1Member2024-09-300001721484lgvn:AprilTwoThousandTwentyFourPublicOfferingMemberus-gaap:CommonClassAMemberlgvn:CommonWarrantsMember2024-01-012024-09-300001721484lgvn:October2023RegisteredDirectOfferingMemberus-gaap:CommonClassAMember2024-09-300001721484lgvn:ClinicalTrialRevenueMember2023-01-012023-09-300001721484lgvn:SeriesCWarrantsMember2024-09-300001721484lgvn:UMAgreementsMember2024-07-192024-09-300001721484us-gaap:AccruedIncomeReceivableMember2023-12-310001721484us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001721484us-gaap:CommonClassAMemberlgvn:JuneInducementWarrantsMember2024-09-300001721484us-gaap:PatentsMember2024-09-300001721484lgvn:PlacementAgentWarrantsMemberlgvn:October2023RegisteredDirectOfferingMemberus-gaap:CommonClassAMember2024-01-012024-09-300001721484us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001721484lgvn:AccountsReceivableFromCustomersMember2024-09-3000017214842024-07-102024-07-100001721484us-gaap:FairValueInputsLevel1Memberus-gaap:AccruedIncomeReceivableMember2024-09-300001721484us-gaap:AdditionalPaidInCapitalMember2023-12-3100017214842016-12-230001721484lgvn:SeriesCUnitsMember2016-12-232016-12-230001721484us-gaap:RetainedEarningsMember2024-01-012024-09-300001721484lgvn:CommonWarrantsMember2024-01-012024-09-300001721484us-gaap:RetainedEarningsMember2024-09-300001721484us-gaap:CommonClassAMember2024-11-080001721484lgvn:PlacementAgentWarrantsMemberlgvn:December2023OfferingMemberus-gaap:CommonClassAMember2024-01-012024-09-3000017214842024-09-3000017214842024-07-170001721484lgvn:ClassACommonStockWarrantsMemberus-gaap:CommonClassAMember2024-04-160001721484us-gaap:CommonClassAMemberlgvn:JulyRegisteredDirectOfferingMember2024-09-300001721484lgvn:AprilTwoThousandTwentyFourPublicOfferingMemberlgvn:PlacementAgentWarrantsMemberus-gaap:CommonClassAMember2024-09-300001721484srt:MinimumMemberus-gaap:FiniteLivedIntangibleAssetsMember2024-09-3000017214842014-11-200001721484lgvn:TwoThousandTwentyOnePIPEOfferingMemberus-gaap:CommonClassAMemberus-gaap:WarrantMember2024-01-012024-09-300001721484lgvn:CommonWarrantsMember2024-04-080001721484lgvn:SecondTrancheJulyOrdinaryCoursePlacementAgentWarrantsMemberus-gaap:CommonClassAMember2024-09-300001721484us-gaap:RetainedEarningsMember2023-06-300001721484us-gaap:CommonClassAMember2024-07-242024-07-2400017214842024-08-060001721484us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-3000017214842016-12-162016-12-220001721484lgvn:LongeveronMember2024-01-012024-09-300001721484us-gaap:RetainedEarningsMember2024-06-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-01-012023-12-310001721484us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-01-012023-09-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-06-300001721484us-gaap:StockOptionMember2023-01-012023-09-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-09-300001721484us-gaap:FairValueInputsLevel2Member2024-09-300001721484lgvn:ChiefScienceOfficerMember2023-12-310001721484us-gaap:ReceivablesFromStockholderMember2023-06-300001721484us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001721484srt:MaximumMember2024-01-012024-09-300001721484us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-3000017214842023-09-300001721484us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001721484us-gaap:CommonClassAMemberlgvn:SeriesDWarrantsMember2024-04-160001721484us-gaap:LicenseMember2024-01-012024-09-300001721484lgvn:December2023OfferingMemberus-gaap:CommonClassAMemberlgvn:InvestorWarrantsMember2024-01-012024-09-300001721484lgvn:PlacementAgentWarrantsMemberus-gaap:CommonClassAMember2024-01-012024-09-300001721484us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001721484us-gaap:AdditionalPaidInCapitalMember2022-12-3100017214842014-11-202014-11-200001721484us-gaap:CommonStockMember2024-09-300001721484lgvn:SeriesCWarrantsMemberus-gaap:CommonClassAMember2024-04-160001721484lgvn:ContractManufacturingMember2024-07-012024-09-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-12-310001721484lgvn:JulyRegisteredDirectOfferingMember2024-07-182024-07-180001721484us-gaap:CommonClassAMember2024-07-172024-07-170001721484us-gaap:FairValueInputsLevel1Member2023-12-310001721484lgvn:TwoThousandTwentyOnePIPEOfferingMemberus-gaap:CommonClassAMemberlgvn:UnderwritersWarrantsMember2024-09-300001721484us-gaap:FairValueInputsLevel3Memberus-gaap:AccruedIncomeReceivableMember2024-09-300001721484us-gaap:NoteWarrantMember2024-07-100001721484us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2024-01-012024-09-3000017214842023-06-300001721484lgvn:ContractManufacturingRevenueMember2024-01-012024-09-300001721484lgvn:ContractManufacturingRevenueMember2024-07-012024-09-300001721484lgvn:BiologicsLicenseMember2014-11-202014-11-200001721484srt:MaximumMember2023-12-310001721484lgvn:SupplyAgreementMemberlgvn:SecretomeTherapeuticsIncorporatedMember2024-07-012024-09-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-09-300001721484lgvn:ContractManufacturingMember2023-01-012023-09-300001721484lgvn:GrantRevenueMember2023-01-012023-09-300001721484us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001721484lgvn:PlacementAgentWarrantsMemberus-gaap:CommonClassAMemberlgvn:October2023RegisteredDirectOfferingMember2024-09-300001721484us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-07-012024-09-3000017214842022-12-310001721484us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-01-012023-12-3100017214842022-11-160001721484lgvn:UMAgreementsMember2023-01-012023-12-3100017214842023-07-012023-09-300001721484us-gaap:FairValueInputsLevel2Memberus-gaap:AccruedIncomeReceivableMember2024-09-300001721484us-gaap:CommonClassBMember2024-09-30xbrli:pureiso4217:USDxbrli:sharesxbrli:sharesiso4217:USD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number: 001-40060

Longeveron Inc.

(Exact name of registrant as specified in its charter)

Delaware

47-2174146

(State or Other Jurisdiction
of Incorporation)

(IRS Employer
Identification No.)

1951 NW 7th Avenue, Suite 520, Miami, Florida

33136

(Address of principal executive offices)

(Zip Code)

(305) 909-0840

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Class A common stock, par value $0.001 per share

LGVN

The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 8, 2024, the registrant had 13,352,770 shares of Class A common stock, $0.001 par value per shares, and 1,484,005 shares of Class B common stock, $0.001 par value per share, outstanding.

 

 


LONGEVERON INC.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

1

ITEM 1.

Condensed Financial Statements

1

Condensed Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023

1

Condensed Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (unaudited)

2

Condensed Statements of Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 (unaudited)

3

Condensed Statements of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2024 and 2023 (unaudited)

4

Condensed Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 (unaudited)

8

Notes to Unaudited Condensed Financial Statements

9

ITEM 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

25

ITEM 3.

Quantitative and Qualitative Disclosures About Market Risk

38

ITEM 4.

Controls and Procedures

39

PART II. OTHER INFORMATION

40

ITEM 1.

Legal Proceedings

40

ITEM 1A.

Risk Factors

40

ITEM 2.

Unregistered Sales of Equity Securities and Use of Proceeds

40

ITEM 3

Defaults Upon Senior Securities

40

ITEM 4

Mine Safety Disclosures

40

ITEM 5

Other Information

40

ITEM 6.

Exhibits

41

SIGNATURES

42

 

i


PART I. FINANCIAL INFORMATION

 

Item 1. Condensed Financial Statements.

 

Longeveron Inc.

Condensed Balance Sheets

(In thousands, except share and per share data)

 

 

September 30,
2024

 

 

December 31,
2023

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

22,778

 

 

$

4,949

 

Marketable securities

 

 

 

 

 

412

 

Prepaid expenses and other current assets

 

 

609

 

 

 

376

 

Accounts and grants receivable

 

 

380

 

 

 

111

 

Total current assets

 

 

23,767

 

 

 

5,848

 

Property and equipment, net

 

 

2,622

 

 

 

2,529

 

Intangible assets, net

 

 

2,347

 

 

 

2,287

 

Operating lease asset

 

 

970

 

 

 

1,221

 

Other assets

 

 

203

 

 

 

193

 

Total assets

 

$

29,909

 

 

$

12,078

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

887

 

 

$

638

 

Accrued expenses

 

 

1,479

 

 

 

2,152

 

Current portion of lease liability

 

 

616

 

 

 

593

 

Deferred revenue

 

 

118

 

 

 

506

 

Total current liabilities

 

 

3,100

 

 

 

3,889

 

Long-term liabilities:

 

 

 

 

 

 

Lease liability

 

 

983

 

 

 

1,448

 

Other liabilities

 

 

199

 

 

 

 

Total long-term liabilities

 

 

1,182

 

 

 

1,448

 

Total liabilities

 

 

4,282

 

 

 

5,337

 

Commitments and contingencies (Note 9)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.001 par value per share, 5,000,000 shares authorized, no shares issued and outstanding at September 30, 2024, and December 31, 2023

 

 

 

 

 

 

Class A common stock, $0.001 par value per share, 84,295,000 shares authorized, 13,352,770 shares issued and outstanding at September 30, 2024; 1,025,183 issued and outstanding at December 31, 2023

 

 

13

 

 

 

1

 

Class B common stock, $0.001 par value per share, 15,705,000 shares authorized, 1,484,005 shares issued and outstanding at September 30, 2024; 1,485,560 issued and outstanding at December 31, 2023

 

 

1

 

 

 

1

 

Additional paid-in capital

 

 

131,139

 

 

 

91,823

 

Stock subscription receivable

 

 

 

 

 

(100

)

Accumulated deficit

 

 

(105,525

)

 

 

(84,984

)

Accumulated other comprehensive loss

 

 

(1

)

 

 

 

Total stockholders’ equity

 

 

25,627

 

 

 

6,741

 

Total liabilities and stockholders’ equity

 

$

29,909

 

 

$

12,078

 

 

See accompanying notes to unaudited condensed financial statements.

 

1


Longeveron Inc.

Condensed Statements of Operations

(In thousands, except per share data)

(Unaudited)

 

 

Three months ended
September 30,

 

 

Nine months ended
September 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

 

Clinical trial revenue

 

$

210

 

 

$

150

 

 

$

1,012

 

 

$

605

 

Contract manufacturing revenue

 

 

563

 

 

 

-

 

 

 

777

 

 

 

-

 

Grant revenue

 

 

-

 

 

 

-

 

 

 

-

 

 

 

41

 

Total revenues

 

 

773

 

 

 

150

 

 

 

1,789

 

 

 

646

 

Cost of revenues

 

 

91

 

 

 

96

 

 

 

435

 

 

 

423

 

Gross profit

 

 

682

 

 

 

54

 

 

 

1,354

 

 

 

223

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

3,125

 

 

 

3,372

 

 

 

7,447

 

 

 

8,902

 

Research and development

 

 

2,206

 

 

 

1,843

 

 

 

6,148

 

 

 

6,910

 

Total operating expenses

 

 

5,331

 

 

 

5,215

 

 

 

13,595

 

 

 

15,812

 

Loss from operations

 

 

(4,649

)

 

 

(5,161

)

 

 

(12,241

)

 

 

(15,589

)

Other income

 

 

 

 

 

 

 

 

 

 

 

 

Other income, net

 

 

230

 

 

 

55

 

 

 

349

 

 

 

204

 

Total other income, net

 

 

230

 

 

 

55

 

 

 

349

 

 

 

204

 

Net loss

 

$

(4,419

)

 

$

(5,106

)

 

$

(11,892

)

 

$

(15,385

)

Deemed dividend – warrant inducement offers

 

 

(149

)

 

 

(798

)

 

 

(8,650

)

 

 

(798

)

Net loss attributable to common stockholders

 

$

(4,568

)

 

$

(5,904

)

 

$

(20,542

)

 

$

(16,183

)

Basic and diluted net loss per share

 

$

(0.34

)

 

$

(2.79

)

 

$

(2.71

)

 

$

(7.29

)

Basic and diluted weighted average common shares outstanding

 

 

13,627,793

 

 

 

2,117,877

 

 

 

7,572,601

 

 

 

2,110,646

 

 

See accompanying notes to unaudited condensed financial statements.

2


Longeveron Inc.

Condensed Statements of Comprehensive Loss

(In thousands)

(Unaudited)

 

 

Three months ended
September 30,

 

 

Nine months ended
September 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Net loss

 

$

(4,419

)

 

$

(5,106

)

 

$

(11,892

)

 

$

(15,385

)

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Net unrealized gain (loss) on available-for-sale securities

 

 

-

 

 

 

26

 

 

 

(1

)

 

 

48

 

Total comprehensive loss

 

$

(4,419

)

 

$

(5,080

)

 

$

(11,893

)

 

$

(15,337

)

 

See notes to unaudited condensed financial statements.

3


Longeveron Inc.

Condensed Statements of Changes in Stockholders’ Equity

(In thousands, except share amounts)

(Unaudited)

 

 

Class A
Common Stock

 

 

Class B
Common Stock

 

 

Subscription

 

 

Additional
Paid-In

 

 

Accumulated

 

 

Accumulated
Other
Comprehensive

 

 

Total
Stockholders’

 

 

Number

 

 

Amount

 

 

Number

 

 

Amount

 

 

Receivable

 

 

Capital

 

 

Deficit

 

 

Loss

 

 

Equity

 

Balance at December 31, 2023

 

 

1,025,183

 

 

$

1

 

 

 

1,485,560

 

 

$

1

 

 

$

(100

)

 

$

91,822

 

 

$

(84,983

)

 

$

-

 

 

$

6,741

 

Conversion of Class B common stock for Class A common stock

 

 

1,555

 

 

 

 

 

 

(1,555

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Class A common stock, issued for RSUs vested

 

 

482,246

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Class A common stock, held for taxes on RSUs vested

 

 

(109,461

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(296

)

 

 

 

 

 

 

 

 

(296

)

Class A common stock, issued for PSUs vested

 

 

8,002

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Class A common stock, held for taxes on PSUs vested

 

 

(3,268

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(17

)

 

 

-

 

 

 

-

 

 

 

(17

)

Collection of stock subscription receivable

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

100

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

100

 

Equity-based compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,938

 

 

 

-

 

 

 

-

 

 

 

1,938

 

Unrealized gain attributable to change in market value of available for sale investments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1

)

 

 

(1

)

Class A common stock issued in public offering, net of issuance cost of $2,064

 

 

4,448,792

 

 

 

4

 

 

 

 

 

 

 

 

 

 

 

 

12,862

 

 

 

-

 

 

 

-

 

 

 

12,866

 

Class A common stock issue for warrants exercised, net of issuance cost of $1,855

 

 

7,432,751

 

 

 

8

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

16,180

 

 

 

-

 

 

 

-

 

 

 

16,188

 

Deemed dividend – warrant inducement offers

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

8,650

 

 

 

(8,650

)

 

 

-

 

 

 

-

 

Reverse stock split rounding adjustment

 

 

66,970

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(11,892

)

 

 

-

 

 

 

(11,892

)

Balance at September 30, 2024

 

 

13,352,770

 

 

$

13

 

 

 

1,484,005

 

 

$

1

 

 

$

-

 

 

$

131,139

 

 

$

(105,525

)

 

$

(1

)

 

$

25,627

 

 

See notes to unaudited condensed financial statements.

4


Longeveron Inc.

Condensed Statements of Changes in Stockholders’ Equity

(In thousands, except share amounts)

(Unaudited)

 

 

Class A
Common Stock

 

 

Class B
Common Stock

 

 

Subscription

 

 

Additional
Paid-In

 

 

Accumulated

 

 

Accumulated
Other
Comprehensive

 

 

Total
Stockholders’

 

 

Number

 

 

Amount

 

 

Number

 

 

Amount

 

 

Receivable

 

 

Capital

 

 

Deficit

 

 

(Loss) Gain

 

 

Equity

 

Balance at December 31, 2022

 

 

612,732

 

 

$

1

 

 

 

1,489,109

 

 

$

1

 

 

$

(100

)

 

$

83,731

 

 

$

(62,773

)

 

$

(357

)

 

$

20,503

 

Conversion of Class B common stock into Class A common stock

 

 

3,555

 

 

 

-

 

 

 

(3,555

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Class A common stock, issued for RSUs vested

 

 

22,703

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Class A common stock, held for taxes on RSUs vested

 

 

(4,305

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(153

)

 

 

-

 

 

 

-

 

 

 

(153

)

Class A common stock issued for stock rights offering

 

 

10,850

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Equity-based compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,619

 

 

 

-

 

 

 

-

 

 

 

1,619

 

Unrealized gain attributable to change in market value of available for sale investments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

48

 

 

 

48

 

Dividend attributable to down round feature of 2021 warrants

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

798

 

 

 

(798

)

 

 

-

 

 

 

-

 

Reverse stock split rounding adjustment

 

 

-

 

 

 

-

 

 

 

6

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(15,385

)

 

 

-

 

 

 

(15,385

)

Balance at September 30, 2023

 

 

645,535

 

 

$

1

 

 

 

1,485,560

 

 

$

1

 

 

$

(100

)

 

$

85,995

 

 

$

(78,956

)

 

$

(309

)

 

$

6,632

 

 

See notes to unaudited condensed financial statements.

5


Longeveron Inc.

Condensed Statements of Changes in Stockholders’ Equity

(In thousands, except share amounts)

(Unaudited)

 

 

Class A
Common Stock

 

 

Class B
Common Stock

 

 

Subscription

 

 

Additional
Paid-In

 

 

Accumulated

 

 

Accumulated
Other
Comprehensive

 

 

Total
Stockholder’s

 

 

Number

 

 

Amount

 

 

Number

 

 

Amount

 

 

Receivable

 

 

Capital

 

 

Deficit

 

 

Loss

 

 

Equity

 

Balance at June 30, 2024

 

 

8,116,909

 

 

$

8

 

 

 

1,484,005

 

 

$

1

 

 

$

-

 

 

$

115,858

 

 

$

(100,957

)

 

$

(1

)

 

$

14,909

 

Class A Common Stock, issued for RSUs vested

 

 

472,532

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Class A Common Stock, held for taxes on RSUs vested

 

 

(105,960

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(270

)

 

 

-

 

 

 

-

 

 

 

(270

)

Equity-based compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,413

 

 

 

-

 

 

 

-

 

 

 

1,413

 

Class A common stock issued in public offering, net of issuance costs of $919

 

 

2,236,026

 

 

 

2

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

8,142

 

 

 

-

 

 

 

-

 

 

 

8,144

 

Class A common stock issued for warrants exercised, net of issuance costs of $494

 

 

2,633,263

 

 

 

3

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

5,847

 

 

 

-

 

 

 

-

 

 

 

5,850

 

Deemed dividend – warrant inducement offers

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

149

 

 

 

(149

)

 

 

-

 

 

 

-

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(4,419

)

 

 

-

 

 

 

(4,419

)

Balance at September 30, 2024

 

 

13,352,770

 

 

$

13

 

 

 

1,484,005

 

 

$

1

 

 

$

-

 

 

$

131,139

 

 

$

(105,525

)

 

$

(1

)

 

$

25,627

 

 

See accompanying notes to unaudited condensed financial statements.

6


Longeveron Inc.

Condensed Statements of Changes in Stockholders’ Equity

(In thousands, except share amounts)

(Unaudited)

 

 

Class A
Common Stock

 

 

Class B
Common Stock

 

 

Subscription

 

 

Additional
Paid-In

 

 

Accumulated

 

 

Accumulated
Other
Comprehensive

 

 

Total
Stockholder’s

 

 

Number

 

 

Amount

 

 

Number

 

 

Amount

 

 

Receivable

 

 

Capital

 

 

Deficit

 

 

(Loss) Gain

 

 

Equity

 

Balance at June, 2023

 

 

631,423

 

 

$

1

 

 

 

1,485,560

 

 

$

1

 

 

$

(100

)

 

$

84,748

 

 

$

(73,052

)

 

$

(335

)

 

$

11,263

 

Class A Common Stock, issued for RSUs vested

 

 

4,731

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Class A Common Stock, held for taxes on RSUs vested

 

 

(1,469

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(50

)

 

 

-

 

 

 

-

 

 

 

(50

)

Class A common stock issued for stock rights offering

 

 

10,850

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

-

 

 

 

-

 

 

 

-

 

Equity-based compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

499

 

 

 

-

 

 

 

-

 

 

 

499

 

Unrealized gain attributable to change in market value of available-for-sale securities

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

26

 

 

 

26

 

Dividend attributable to down round feature of 2021 warrants

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

798

 

 

 

(798

)

 

 

-

 

 

 

-

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(5,106

)

 

 

-

 

 

 

(5,106

)

Balance at September 30, 2023

 

 

645,535

 

 

$

1

 

 

 

1,485,560

 

 

$

1

 

 

$

(100

)

 

$

85,995

 

 

$

(78,956

)

 

$

(309

)

 

$

6,632

 

 

See accompanying notes to unaudited condensed financial statements.

7


Longeveron Inc.

Condensed Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

Nine months ended
September 30,

 

 

2024

 

 

2023

 

Cash flows from operating activities

 

 

 

 

 

 

Net loss

 

$

(11,892

)

 

$

(15,385

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

716

 

 

 

710

 

Interest earned on marketable securities

 

 

60

 

 

 

180

 

Equity-based compensation

 

 

1,938

 

 

 

1,619

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts and grants receivable

 

 

(269

)

 

 

122

 

Prepaid expenses and other current assets

 

 

(233

)

 

 

(611

)

Other assets

 

 

(10

)

 

 

47

 

Accounts payable

 

 

248

 

 

 

(922

)

Deferred revenue

 

 

(387

)

 

 

 

Nonoperating lawsuit liability

 

 

 

 

 

(1,398

)

Accrued expenses

 

 

(674

)

 

 

823

 

Operating lease asset and lease liability

 

 

(191

)

 

 

(190

)

Other liabilities

 

 

199

 

 

 

 

Net cash used in operating activities

 

 

(10,495

)

 

 

(15,005

)

Cash flows from investing activities

 

 

 

 

 

 

Proceeds from the sale of marketable securities

 

 </